

ALT5 Sigma Corporation's Crypto-as-a-Service Platform Enables Stablecoin Management, Integration, and Utility Across All Leading Blockchains

written by Raj Shah | June 30, 2025

Regulated entities can streamline stablecoin operations – permissioned or permissionless – using ALT5 Sigma's Crypto-as-a-Service platform, fully compatible with proprietary and third-party assets.

June 30, 2025 ([Source](#)) – ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1), a leading provider of Crypto-as-a-Service infrastructure, has launched a comprehensive stablecoin management solution for U.S. institutions. Designed for regulated entities, the platform enables seamless integration, utilization, and oversight of stablecoins-regardless of the issuing entity or blockchain protocol. Whether managing proprietary tokens or leveraging market leaders, institutions can operationalize, monitor, and scale stablecoin use through ALT5 Sigma's infrastructure. Integration with existing workflows and systems is supported via robust APIs.

“Stablecoins represent a critical bridge between traditional finance and the blockchain economy,” said **Ron Pitters**, Chief Operating Officer of ALT5 Sigma Corporation. “We’re focused on removing operational barriers so institutions can maximize the utility of stablecoins they already trust-whether issued in-house or sourced externally. By integrating stablecoins into enterprise systems, we enable real-time payments, automated

settlements, and streamlined treasury functions-without requiring custom blockchain development.”

ALT5 Sigma’s infrastructure supports both permissioned and permissionless stablecoins, enabling institutions to:

- Integrate stablecoins into core operations, regardless of the blockchain or issuance model
- Manage risk, compliance, and wallet infrastructure through built-in KYC/AML and monitoring tools
- Connect to internal systems via APIs, including treasury, ERP, CRM, and banking platforms
- Enable programmable flows, such as recurring disbursements, settlement automation, and cross-border transfers

Seamless Support for Industry-Leading Stablecoins

The ALT5 Sigma platform already supports the world’s largest and most liquid stablecoins, including Tether (USDT), USD Coin (USDC), World Liberty Financial (USD1), EURC (EURC), and many others.

A Regulatory Tailwind: The Transformational Impact of the GENIUS Act

The GENIUS Act (Guaranteed and Enhanced National Interest in the United States Stablecoins Act), recently passed by the U.S. Senate, marks a pivotal moment for the regulated adoption of digital assets. As it heads to the House of Representatives, the Act outlines clear requirements for 1:1 reserves in high-quality liquid assets, licensing for issuers exceeding \$10 billion in circulation, monthly audits and transparency reports, and robust anti-money laundering provisions.

ALT5 Sigma's stablecoin framework is fully aligned with these emerging standards, ensuring compliance and operational integrity from day one.

ALT5 Sigma stands ready to help institutions swiftly deploy compliant stablecoins-new or existing-and capitalize this momentum to modernize their payment and treasury operations.

For additional information, please contact: sales@alt5sigma.com

About ALT5 Sigma Corporation

[ALT5 Sigma Corporation](#) (NASDAQ: ALTS) (FRA: 5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. ALT5 has been a constituent of the Russell Microcap Index since June 28, 2024.

Founded in 2018, ALT5 Sigma, Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) enables the migration to a new global financial paradigm through its suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms: "ALT5 Pay" and "ALT5 Prime." The company has processed over \$5 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell

digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.

The Company is also advancing the separation of its biotech business, which will continue under "Alyea Therapeutics Corporation." Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also may contain statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market,

and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company’s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the sections entitled “Risk Factors” in the Company’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media/Investor Relations Contact

IR@alt5sigma.com

1-800-400-2247